Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.46 |
| ▸ | LSS | P48449 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.41 |
| ▸ | PPARD | Q03181 | 5/20 | 0.41 |
| ▸ | PPARA | Q07869 | 5/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8998641 | 1.00 | MEN1 (0.48) | MEN1KMT2AALOX15CYP3A4PTPN1 | |
| SCHEMBL2817240 | 1.00 | MEN1 (0.48) | MEN1KMT2AALOX15CYP3A4PTPN1 | |
| SCHEMBL5560370 | 1.00 | MEN1 (0.48) | MEN1KMT2AALOX15CYP3A4PTPN1 | |
| SCHEMBL8998659 | 1.00 | MEN1 (0.48) | MEN1KMT2AALOX15CYP3A4PTPN1 | |
| SCHEMBL8998633 | 1.00 | MEN1 (0.48) | MEN1KMT2AALOX15CYP3A4PTPN1 | |
| SCHEMBL8998739 | 1.00 | MEN1 (0.48) | MEN1KMT2AALOX15CYP3A4PTPN1 | |
| SCHEMBL8998668 | 1.00 | MEN1 (0.48) | MEN1KMT2AALOX15CYP3A4PTPN1 | |
| SCHEMBL5439961 | 1.00 | MEN1 (0.48) | MEN1KMT2AALOX15CYP3A4PTPN1 | |
| SCHEMBL22556624 | 1.00 | MEN1 (0.48) | MEN1KMT2AALOX15CYP3A4PTPN1 | |
| SCHEMBL8998731 | 1.00 | MEN1 (0.48) | MEN1KMT2AALOX15CYP3A4PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613585-A4 | COMPOUNDS AND METHODS FOR USE IN TREATING NEOPLASIA AND CANCER BASED UPON INHIBITORS OF ISOPRENYLCYSTEINE METHYLTRANSFERASE | PURDUE RESEARCH FOUNDATION (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070004803-A1 | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase | PURDUE RESEARCH FOUNDATION (US) | 2007-01-04 | — | — | US | disclosed |
| EP-1613585-A2 | COMPOUNDS AND METHODS FOR USE IN TREATING NEOPLASIA AND CANCER BASED UPON INHIBITORS OF ISOPRENYLCYSTEINE METHYLTRANSFERASE | PURDUE RESEARCH FOUNDATION (US) | 2006-01-11 | — | — | EP | disclosed |
| US-6835846-B2 | The present invention provides an aliphatic compound represented by the following formula (I) or pharmacologically acceptable salts thereof: the aliphatic compound being an optical isomer of the (2R,3S,2'S) configuration when the | MARUHA CORPORATION (JP) | 2004-12-28 | — | — | US | disclosed |
| WO-2004087064-A2 | COMPOUNDS AND METHODS FOR USE IN TREATING NEOPLASIA AND CANCER BASED UPON INHIBITORS OF ISOPRENYLCYSTEINE METHYLTRANSFERASE | PURDUE RESEARCH FOUNDATION (US) | 2004-10-14 | — | — | WO | disclosed |
| US-20040014816-A1 | Novel aliphatic compounds, process for their preparation and their usage | MARUHA NICHIRO SEAFOODS, INC. (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1325904-A1 | NOVEL ALIPHATIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USAGE | Maruha Corporation (JP) | 2003-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004803-A1 | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase | BHMT, BHMT2, GNMT | MEN1 924/4885KMT2A 601/4885ALOX15 527/4885 |
| US-20040014816-A1 | Novel aliphatic compounds, process for their preparation and their usage | CPT1B, ACSS2, CERS2 | MEN1 1555/4885KMT2A 4077/4885ALOX15 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.